First-ever oral GLP-1 pill shows real promise for sleep apnea

A daily pill for sleep apnea could be on the horizon

Two phase III ATTAIN-OSA trials presented at the American Heart Association Scientific Sessions — and simultaneously published in JAMA — found that orforglipron (Foundayo), an oral GLP-1 receptor agonist made by Eli Lilly, significantly reduced sleep apnea severity in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight. The drug, already FDA-approved for weight management, could become the first-ever oral treatment specifically for OSA if approved for that indication.

Right now, OSA is primarily managed with CPAP machines or oral appliances — devices that work well but are notoriously hard to stick with. An oral pill option could meaningfully expand access and adherence, especially for the many patients who struggle with or refuse device-based therapy.

By the Numbers

• AHI (apnea-hypopnea index) reduced by ~17–18 events/hour with orforglipron vs. ~5 events/hour with placebo (both PAP and non-PAP groups; P<0.001)
• 72% reduction in sleep apnea-specific hypoxic burden vs. placebo
• 10–11% reduction in body weight vs. 1–2% with placebo
• 7–8 mmHg drop in systolic blood pressure vs. 1–3 mmHg with placebo
• GI side effects reported in ~69% of orforglipron users vs. ~37% on placebo

Why it matters: Sleep apnea affects millions and is strongly linked to cardiovascular disease, hypertension, and diabetes — yet it remains massively undertreated. An oral therapy that also improves cardiometabolic risk factors could transform how clinicians approach OSA management, particularly for patients who can't or won't use CPAP.